Resources 
    • About Us 

    • Home Report Store Multiplex Assays Market
    Multiplex Assays Market

    Multiplex Assays Market Size, Share, Forecast, & Trends Analysis by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Infectious) Product, End User - Global Forecast to 2031

    Report ID:MRHC - 104915 Pages: 262 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 Hours

    Multiplex Assays Market Size & Forecast

    The Multiplex Assays Market is expected to reach $6.80 billion by 2031 at a CAGR of 8.9% from 2024 to 2031. Multiplex assays are a form of immunoassay that measures several analytes at once. These assays are derived from the conventional ELISA technology, which generates numerous signal measurements instead of only one, as in ELISA. Multiplex assays use microspheres coated with several antibodies that come in various colors. It uses flow cytometry to separate various colored beads by their diverse degrees of fluorescence, the findings of which are read following incubation.

    The growth of this market is attributed to several factors: the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, rising use of multiplex assays in drug discovery, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.

    The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine are expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges to market growth.

    Multiplex Assays Market Growth Drivers

    Advantages of Multiplex Assays over Singleplex Assays

    In recent years, scientists and researchers have increasingly adopted multiplex assays due to their advantages over singleplex assays. Multiplex assays generate more reproducible and robust results compared to singleplex assays. These assays are more reliable than singleplex assays, can simultaneously analyze multiple analytes, reduce the chances of human error, and offer more accurate results. Additionally, multiplex assays use similar experimental criteria for all analytes, making experiment results more easily comparable.

    The main advantage multiplex assays offer over singleplex assays is their lower sample requirement. The multiplex approach uses lower quantities of samples, reducing associated costs and providing all the required data points from a single reaction. Although singleplex assays are simpler to perform than multiplex assays, the results are more accurate and informative, which drives the preference for multiplex assays among end users.

    Click here to: Get Free Sample Pages of this Report

    Use of Multiplex Assays in Drug Discovery

    Pharmaceutical & biotechnology companies allocate significant resources for drug discovery & development. The increasing prevalence of chronic diseases is increasing the need for the development of novel therapies, thus focus on drug discovery is increasing. Multiplex assays have become increasingly important in maintaining precision and accuracy in drug research and development and reducing the time required for research purposes. Multiplex assays are used in biomarker discovery and validation. Identifying and characterizing biomarkers can streamline the drug candidate selection process, thus reducing the number of failures in clinical trials and enabling the discovery of more effective therapeutics hence adopted.

    The funding for drug discovery is also increasing, which is driving the demand for multiplex assays. For instance, in March 2023, the Government of Canada provided a fund of USD 59 million to the Canadian Critical Drug Initiative to boost drug research, commercialization, and manufacturing in the Alberta province.

    Multiplex Assays Market Trends

    Integration of Artificial Intelligence

    Disease diagnosis often requires identifying candidate pathogenic variants and determining the correspondence between the diseased individual’s phenotype and pathogenic variant. The integration of AI algorithms into multiplex assays can significantly enhance phenotype-genotype mapping. In molecular diagnostics, automated systems are also used to accurately spot target genes and design oligonucleotide primers, which are important in developing multiplex assays. By compiling data from assay development, diagnostics companies can artificially find the most efficient genetic target for developing a specific multiplexed assay.

    Using AI, companies can speed up the development of diagnostic tests by automating the assay designing phase. AI is also incorporated in multiplex assays for drug discovery and design. AI plays a crucial role in drug repurposing, drug target identification & validation, multi-target drug discovery, and biomarker identification. For instance, Seegene, Inc. (South Korea) developed the first multiplex assay with an AI-based system. AI developed the entire assay in just four days. The assay is used to simultaneously detect eight different DNA targets for sexually transmitted infections and meningitis.

    Development of Smartphone-based Diagnostic Testing Platforms

    The demand for high-quality medical services is rising continuously. Smartphone-based platforms find applications in tele-imaging, food technology, and education. Smartphone-based detection is versatile and has a wide range of medical applications. Diagnostic multiplex assays play an important role in simultaneously detecting multiple pathogens. With high diagnosis costs and the limited availability of benchtop readers in remote/resourceless areas, the demand for smartphone-based multiplex diagnostics is rising continuously. These smartphone-based end-to-end platforms are complemented with deep learning methods to further increase device efficiency. These smartphone-based detection methods provide automated detection and analysis of the results and support human expertise. The transactions involved in patient data handling are secured via blockchain technology. For instance, Luminostics, Inc. (U.S.) received the FDA’s Emergency Use Authorization (EUA) for its Clip COVID Rapid Antigen Test, a rapid (results generated in 15 minutes), smartphone-connected antigen immunoassay that uses glow-in-the-dark nanomaterials to detect and differentiate SARS-CoV-2 and influenza A/B.

    Multiplex Assays Market Opportunities

    Increasing Focus on Personalized Medicine

    Personalized/precision medicine uses an individual’s genomic information to offer targeted treatment. Multiplex assays can simultaneously detect multiple biomarkers, driving their utilization in precision medicine. Multiplex assay approaches are used to identify changes in gene expression, genetic variations, or epigenetic modifications associated with a particular disease or condition; thus, these assays are useful in developing personalized medicines.

    Additionally, cell-based multiplexing is an important aspect of personalized medicine as it creates a cell or tissue-specific spatial context for extending, interpreting, and understanding the information captured from multiple biomarkers, which can be important in guiding treatment decisions in personalized medicine.

    According to an article published in the MDPI journal in 2020, multiplex immunoassays provide an overall understanding of the disease and pathways involved in Rheumatoid Arthritis (RA) and simultaneously analyze multiple proteins that can yield biomarker signatures of RA subtypes to enable patients to benefit from personalized medicine.

    Multiplex Assays Market Analysis: Key Findings

    By Type: In 2024, the Protein Multiplex Assays Segment to Dominate the Multiplex Assays Market

    Based on type, the multiplex assays market is segmented into protein multiplex assays, nucleic acid multiplex assays, and cell-based multiplex assays. In 2024, the protein multiplex assays segment is expected to account for the largest share of 53.3% of the multiplex assays market. Protein multiplex assays are segmented into bead-based assays and planar assays. In 2024, the bead-based assays segment is expected to account for the largest share of the protein multiplex assays market. Multiplex bead-based assays have become essential tools for diagnosing various diseases. These assays are used for testing allergies, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine diseases. Their increasing application areas in clinical diagnostics and R&D are driving the market's growth. Also, bead-based assays require a limited sample volume and less time, thus making it a preferable technique for studies or experiments of many factors, such as pituitary hormones and cytokines, thereby contributing to the largest share of the segment.  

    By Product: In 2024, the Consumables Segment to Dominate the Multiplex Assays Market

    Based on product, the multiplex assays market is segmented into consumables, instruments, and software & services. In 2024, the consumables segment is expected to account for the largest share of the multiplex assays market. Diagnostic kits are designed to provide highly accurate results with minimal risk of user error. They are pre-packaged with all the necessary materials and reagents, ensuring that the correct amounts are used while reducing the risk of contamination. Assay kits are used in various applications, including COVID-19 diagnosis, infectious disease testing, oncology, cardiovascular, and other applications, contributing to the largest share of the segment.

    By Technology: In 2024, the Flow Cytometry Segment to Dominate the Multiplex Assays Market

    Based on technology, the multiplex assays market is segmented into flow cytometry, multiplex real-time PCR, multiplex immunoassay, sequencing, and other technologies. In 2024, the flow cytometry segment is expected to account for the largest share of 40.0% of the multiplex assays market.  Flow cytometry technology is preferred over other technologies due to its rapid, high-throughput, and sensitive results. Its reproducible detection capabilities make it ideal for various biomedical applications requiring multiplex protein or nucleic acid analyte detection. Additionally, the high penetration of flow cytometry in both research & development and clinical diagnosis contributes to the largest share of the segment.

    By Application: In 2024, the Research & Development Segment to Dominate the Multiplex Assays Market

    Based on application, the multiplex assays market is segmented into research & development and clinical diagnosis applications. In 2024, the research & development segment is expected to account for the largest share of the multiplex assays market. Multiplex assays are increasingly used in the research & development of personalized medicines and research programs for understanding disease mechanisms. Furthermore, increasing pharmaceutical research & development spending, rising new molecular entity approvals, and the launch of multiplex assay panels for research applications by the key players contribute to the largest share of the segment.

    By End User: In 2024, the Pharmaceutical & Biotechnology Companies Segment to Dominate the Multiplex Assays Market

    Based on end user, the multiplex assays market is segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, hospitals, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market. The rising number of research laboratories, increasing investment in R&D, and rising funding for research laboratories support the largest share of the market.  The funding for research laboratories is increasing due to the increasing demand for new drugs and therapies and advancements in laboratory equipment. For instance, in 2021, the U.S. Federal Government invested USD 179.5 billion in R&D. (Source: U.S. Government Accountability Office). Additionally, pharmaceutical companies are increasingly partnering with CROs for product development. The expansion of CROs to meet the growing demand for new product development also supports the market's largest share.

    Geographical Analysis

    In 2024, North America to Dominate the Market

    In 2024, North America is expected to account for the largest share of 39.2% of the multiplex assays market. The large market share of this region is attributed to the high prevalence of chronic and infectious diseases, awareness regarding early disease diagnosis, high adoption of advanced diagnostic products, and increasing funding activities. According to the U.S. Department of Health & Human Services, in 2022, the National Institute of Health (NIH) allocated USD 45 billion for biomedical research. Moreover, the government partnership with key players for the development of multiplex assay, rising prevalence of cancer, strong academic research, and the presence of key players are contributing to the largest share of the market.

    Asia-Pacific is expected to grow at the highest CAGR of 10.8% during the forecast period. The growth of the multiplex assays market in Asia-Pacific is attributed to the rising research funding in the healthcare and pharmaceutical industry, the rising number of research laboratories, the advancing research framework, and the growing number of diagnostic laboratories in countries such as China, India, Japan, South Korea, and others. For instance, in 2022, the R&D spending of BeiGene Ltd. (China), one of the major pharmaceutical companies, increased by 12.4% from 2021. The increasing use of multiplex immunoassay in precision medicine and government initiatives for precision medicine is also driving the market growth.

    Multiplex Assays Market: Key Companies

    The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years . The key players operating in the multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).

    Multiplex Assay Market Overview: Latest Developments from Key Industry Players

    • In April 2023, Seegene, Inc. (South Korea) partnered with the International Vaccine Institute (IVI) (South Korea) to utilize Seegene's HPV diagnostic reagent for conducting HPV tests in approximately 50,000 people across eight Asian and African countries for up to five years from August.

    • In April 2023, QIAGEN N.V. (Netherlands) launched the QIAstat-Dx syndromic testing solution and SARS-CoV-2 Respiratory Panel in Japan. The SARS-CoV-2 Respiratory Panel detects more than 20 pathogens from a single patient sample.

    • In February 2023, F. Hoffmann-La Roche Ltd. (Switzerland) collaborated with Janssen Biotech Inc. (U.S.) to create multiple companion diagnostic technologies, including immunoassays, digital pathology, PCR, next-generation sequencing, and immunohistochemistry.
    • In February 2023, Thermo Fisher Scientific, Inc. (U.S.) launched ‘Applied Biosystems TaqPath’ PCR kits for infectious diseases such as genetic analysis (HLA B27), Multi-Drug Resistant Tuberculosis (MTB MDR), Human Immunodeficiency Virus (HIV), M. Tuberculosis complex (MTB), Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV). The kits also have received licensing rights from the Central Drugs Standard Control Organization (CDSCO) and are manufactured in India in association with Mylab Discovery Solutions (India).

    Multiplex Assays Market Research Summary:

    Particulars

    Details

    Number of Pages

     262

    Format

     PDF

    Forecast Period

     2024-2031

    Base Year

     2023

    CAGR

     8.9%

    Estimated Market Size (Value)

     $6.80 billion by 2031

    Segments Covered

    By Type

    • Protein Multiplex Assays
      • Bead-based Assays
      • Planar Assay
    • Nucleic Acid Multiplex Assays
    • Cell-based Multiplex Assays

    By Product

    • Consumables
    • Instruments
    • Software & Services

    By Technology

    • Flow Cytometry
    • Multiplex Immunoassay
    • Multiplex Real-Time PCR
    • Sequencing
    • Other Technologies
      (Note: Other technologies consist of microarray and immunohistochemistry)

    By Application

    • Research & Development
    • Clinical Diagnosis
      • Infectious Diseases
      • Oncology
      • Cardiovascular Diseases
      • Autoimmune Diseases
      • Other Diseases
        (Note: Other diseases include neurological diseases, thrombosis, and drug abuse testing.)

    By End User

    • Pharmaceutical & Biotechnology Companies
    • Diagnostic Laboratories
    • Hospitals
    • Other End Users
      (Note: Other end users consist of academic institutes & research centers, forensic labs, agriculture companies, and food & beverage companies)

    Countries Covered

    North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa

    Key Companies

    The key players operating in the multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).

    Key questions answered in the multiplex assays market report:

    The multiplex assays market covers the study of various segments, including type, product, technology, application, and end-user at regional and country levels. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.

    The multiplex assays market is projected to reach $6.80 billion by 2031 at a CAGR of 8.9% during the forecast period.

    Among the types, the protein multiplex assays segment is estimated to hold a major market share in 2024. Increasing use of protein multiplex assays for the simultaneous detection of the protein analytes in the sample. Protein multiplex assays are used to simultaneously detect chemokine, growth factors, cytokines, and others, which are the major factors for understanding the disease mechanism.

    The growth of this market is attributed to several factors: the advantages of multiplex assays over singleplex assays, the growing use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine are expected to generate growth opportunities for the players operating in this market.

    The key players operating in the multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).

    The emerging countries in the Asian-Pacific are projected to offer significant growth opportunities for the vendors in this market due to the advancing healthcare infrastructure, increasing research laboratories, and rising research funding in the healthcare & pharmaceutical industry.

    Enquire
    Check Discount
    Related Tag: Multiplex Assays Market Multiplex Immunoassay Multiplex ELISA Luminex assay Bead Based Assay Bead Based Immunoassay Multianalyte assays Multiplex Flow Assays Multiplex Flow Cytometry
    In Vitro Diagnostics
    Healthcare

    1.  Introduction
        1.1.  Market Definition
        1.2.  Market Ecosystem
        1.3.  Currency and Limitations
        1.4.  Key Stakeholders

    2.  Research Methodology
        2.1.  Research Approach
        2.2.  Process of Data Collection and Validation
            2.2.1.  Secondary Research
            2.2.2.  Primary Research/Interviews with Key Opinion Leaders of the Industry
        2.3.  Market Sizing and Forecasting
            2.3.1.  Market Size Estimation Approach
            2.3.2.  Growth Forecast Approach
        2.4.  Assumptions for the Study

    3.  Executive Summary

    4.  Market Insights
        4.1.  Overview
        4.2.  Factors Affecting Market Growth
            4.2.1.  Market Dynamics
                4.2.1.1.  Advantages of Multiplex Assays over Singleplex Assays Leading to their Increased Adoption
                4.2.1.2.  Growing Use of Multiplexing in Companion Diagnostics Driving the Demand for Multiplex Assays
                4.2.1.3.  High Costs of Multiplex Assay Equipment Hampering Adoption Among End Users
                4.2.1.4.  Increasing Focus on Personalized Medicine Boosting the Utilization of Multiplex Assays
                4.2.1.5.  Shortage of Skilled Professionals and the Risk of Cross-reactivity Limiting the Adoption of Multiplex Assays
            4.2.2.  Factor Analysis
        4.3.  Technology Trends
            4.3.1.  Technological Advancements in Multiplex PCR Technology
            4.3.2.  Integration of Artificial Intelligence and Machine Learning into Multiplex Assay Systems
            4.3.3.  Development of Smartphone-based Diagnostic Testing Platforms
        4.4.  Regulatory Analysis
            4.4.1.  North America
                4.4.1.1.  U.S.
                4.4.1.2.  Canada
            4.4.2.  Europe
            4.4.3.  Asia-Pacific
                4.4.3.1.  China
                4.4.3.2.  India
                4.4.3.3.  Japan
                4.4.3.4.  South Korea
            4.4.4.  Latin America
            4.4.5.  Middle East & Africa
        4.5.  Pricing Analysis
        4.6.  Porter’s Five Forces Analysis
            4.6.1.  Bargaining Power of Suppliers
            4.6.2.  Bargaining Power of Buyers
            4.6.3.  Threat of Substitutes
            4.6.4.  Threat of New Entrants
            4.6.5.  Degree of Competition

    5.  Multiplex Assays Market Assessment—by Type
        5.1.  Overview
        5.2.  Protein Multiplex Assays
            5.2.1.  Bead-based Assays
            5.2.2.  Planar Assays
        5.3.  Nucleic Acid Multiplex Assays
        5.4.  Cell-based Multiplex Assays

    6.  Multiplex Assays Market Assessment—by Product
        6.1.  Overview
        6.2.  Consumables
        6.3.  Instruments
        6.4.  Software & Services

    7.  Multiplex Assays Market Assessment—by Technology
        7.1.  Overview
        7.2.  Flow Cytometry
        7.3.  Multiplex Immunoassay
        7.4.  Multiplex Real-time PCR
        7.5.  Sequencing
        7.6.  Other Technologies

    8.  Multiplex Assays Market Assessment—by Application
        8.1.  Overview
        8.2.  Research & Development
        8.3.  Clinical Diagnosis
            8.3.1.  Infectious Diseases
            8.3.2.  Oncology
            8.3.3.  Cardiovascular Diseases
            8.3.4.  Autoimmune Diseases
            8.3.5.  Other Diseases

    9.  Multiplex Assays Market Assessment—by End User
        9.1.  Overview
        9.2.  Pharmaceutical & Biotechnology Companies
        9.3.  Diagnostic Laboratories
        9.4.  Hospitals
        9.5.  Other End Users

    10.  Multiplex Assays Market Assessment—by Geography
        10.1.  Overview
        10.2.  North America
            10.2.1.  U.S.
            10.2.2.  Canada
        10.3.  Europe
            10.3.1.  Germany
            10.3.2.  France
            10.3.3.  U.K.
            10.3.4.  Italy
            10.3.5.  Spain
            10.3.6.  Rest of Europe
        10.4.  Asia-Pacific
            10.4.1.  China
            10.4.2.  Japan
            10.4.3.  India
            10.4.4.  Rest of Asia-Pacific
        10.5.  Latin America
            10.5.1.  Brazil
            10.5.2.  Mexico
            10.5.3.  Rest of Latin America
        10.6.  Middle East & Africa

    11.  Competition Analysis
        11.1.  Overview
        11.2.  Key Growth Strategies
        11.3.  Competitive Benchmarking
        11.4.  Competitive Dashboard
            11.4.1.  Industry Leaders
            11.4.2.  Differentiators
            11.4.3.  Vanguards
            11.4.4.  Emerging Companies

    12.  Company Profiles
        12.1.  Seegene, Inc.
        12.2.  F.  Hoffmann-La Roche Ltd.
        12.3.  Thermo Fisher Scientific, Inc.
        12.4.  Illumina, Inc.
        12.5.  QIAGEN N.V.
        12.6.  Becton, Dickinson and Company
        12.7.  Bio-Rad Laboratories, Inc.
        12.8.  DiaSorin S.p.A.
        12.9.  PerkinElmer, Inc.
        12.10.  Agilent Technologies, Inc.
        12.11.  Abbott Laboratories
        12.12.  Siemens Healthineers AG
        12.13.  Merck KGaA
        12.14.  Quanterix Corporation
                   (Note: SWOT analysis is provided for the top 5 companies)

    13.  Appendix
        13.1.  Available Customization
        13.2.  Related Reports

    List of Tables
    Table 1    Estimated Number of New Cancer Cases, by Type (2022 Vs. 2030)    
    Table 2    Some of The Emergency Use Authorizations (EUA) Granted for Multiplex Assays During the Covid-19 Pandemic    
    Table 3    Medical Devices Regulatory Authorities in the Rest of APAC Countries    
    Table 4    IVD Regulatory Systems, by Country    
    Table 5    Average Selling Price of Multiplex Assays Products (Price/ USD)    
    Table 6    Thermo Fisher Scientific, Inc. (U.S.): Multiplex Assays Prices    
    Table 7    R&D Systems (U.S.): Multiplex Assays Prices    
    Table 8    Quanterix Corporation (U.S.): Multiplex Assays Prices    
    Table 9    Global Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 10    Global Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 11    Global Protein Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)    
    Table 12    Global Bead-based Assays Market, by Country/Region, 2022–2031 (USD Million)    
    Table 13    Global Planar Assays Market, by Country/Region, 2022–2031 (USD Million)        
    Table 14    Global Nucleic Acid Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)        
    Table 15    Global Cell-Based Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)        
    Table 16    Global Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 17    Key Companies Offering Consumables for Multiplex Assays    
    Table 18    Global Multiplex Assay Consumables Market, by Country/Region, 2022–2031 (USD Million)        
    Table 19    Global Multiplex Assay Instruments Market, by Country/Region, 2022–2031 (USD Million)
    Table 20    Key Companies Offering Software    
    Table 21    Global Multiplex Assay Software & Services Market, by Country/Region, 2022–2031 (USD Million)    
    Table 22    Global Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 23    Global Multiplex Assays Market for Flow Cytometry, by Country/Region, 2022–2031 (USD Million)        
    Table 24    Global Multiplex Assays Market for Multiplex Immunoassay, by Country/Region, 2022–2031 (USD Million)    
    Table 25    Global Multiplex Assays Market for Multiplex Real-Time PCR, by Country/Region, 2022–2031 (USD Million)    
    Table 26    Global Multiplex Assays Market for Sequencing, by Country/Region, 2022–2031 (USD Million)
    Table 27    Global Multiplex Assays Market for Other Technologies, by Country/Region, 2022–2031 (USD Million)    
    Table 28    Global Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 29    Global Multiplex Assays Market for Research & Development, by Country/Region, 2022–2031 (USD Million)        
    Table 30    Global Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
    Table 31    Global Multiplex Assays Market for Clinical Diagnosis, by Country/Region, 2022–2031 (USD Million)    
    Table 32    COVID-19 Testing Kits    
    Table 33    Global Multiplex Assays Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)    
    Table 34    Global Multiplex Assays Market for Oncology, by Country/Region, 2022–2031 (USD Million)
    Table 35    Global Multiplex Assays Market for Cardiovascular Diseases, by Country/Region, 2022–2031 (USD Million)        
    Table 36    Global Multiplex Assays Market For Autoimmune Diseases, by Country/Region, 2022–2031 (USD Million)    
    Table 37    Global Multiplex Assays Market for Other Diseases, by Country/Region, 2022–2031 (USD Million)        
    Table 38    Global Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 39    Global Multiplex Assays Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)    
    Table 40    Global Multiplex Assays Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)        
    Table 41    Global Multiplex Assays Market for Hospitals, by Country/Region, 2022–2031 (USD Million)
    Table 42    Global Multiplex Assays Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
    Table 43    Global Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)    
    Table 44    North America: Multiplex Assays Market, by Country, 2022–2031 (USD Million)    
    Table 45    North America: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 46    North America: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 47    North America: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 48    North America: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
    Table 49    North America: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 50    North America: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 51    North America: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 52    U.S.: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 53    U.S.: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 54    U.S.: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 55    U.S.: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 56    U.S.: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 57    U.S.: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 58    U.S.: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 59    Canada: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 60    Canada: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 61    Canada: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 62    Canada: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 63    Canada: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 64    Canada: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 65    Canada: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 66    Europe: Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)    
    Table 67    Europe: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 68    Europe: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 69    Europe: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 70    Europe: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 71    Europe: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 72    Europe: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)    
    Table 73    Europe: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 74    Germany: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 75    Germany: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 76    Germany: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 77    Germany: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 78    Germany: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 79    Germany: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 80    Germany: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 81    France: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 82    France: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 83    France: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 84    France: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 85    France: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 86    France: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)    
    Table 87    France: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 88    U.K.: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 89    U.K.: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 90    U.K.: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 91    U.K.: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 92    U.K.: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 93    U.K.: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
    Table 94    U.K.: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 95    Italy: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 96    Italy: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 97    Italy: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 98    Italy: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 99    Italy: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 100    Italy: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 101    Italy: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 102    Spain: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 103    Spain: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 104    Spain: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 105    Spain: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 106    Spain: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 107    Spain: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 108    Spain: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 109    COVID-19 Cases in European Countries    
    Table 110    Rest of Europe: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 111    Rest of Europe: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 112    Rest of Europe: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 113    Rest of Europe: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 114    Rest of Europe: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 115    Rest of Europe: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 116    Rest of Europe: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 117    Asia-Pacific: Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)    
    Table 118    Asia-Pacific: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 119    Asia-Pacific: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 120    Asia-Pacific: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 121    Asia-Pacific: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 122    Asia-Pacific: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 123    Asia-Pacific: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 124    Asia-Pacific: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 125    China: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 126    China: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 127    China: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 128    China: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 129    China: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 130    China: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 131    China: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 132    Japan: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 133    Japan: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 134    Japan: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 135    Japan: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 136    Japan: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 137    Japan: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 138    Japan: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 139    India: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 140    India: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 141    India: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 142    India: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 143    India: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 144    India: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 145    India: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 146    Rest of Asia-Pacific: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 147    Rest of Asia-Pacific: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 148    Rest of Asia-Pacific: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 149    Rest of Asia-Pacific: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 150    Rest of Asia-Pacific: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 151    Rest of Asia-Pacific: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)    
    Table 152    Rest of Asia-Pacific: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 153    Latin America: Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)    
    Table 154    Latin America: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 155    Latin America: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 156    Latin America: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 157    Latin America: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 158    Latin America: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 159    Latin America: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 160    Latin America: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 161    Brazil: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 162    Brazil: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 163    Brazil: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 164    Brazil: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 165    Brazil: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 166    Brazil: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)        
    Table 167    Brazil: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 168    Mexico: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 169    Mexico: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 170    Mexico: Multiplex Assays Market, by Product, 2022–2031 (USD Million)    
    Table 171    Mexico: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 172    Mexico: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 173    Mexico: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 ( USD Million)    
    Table 174    Mexico: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 175    Rest of Latin America: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 176    Rest of Latin America: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
    Table 177    Rest of Latin America: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
    Table 178    Rest of Latin America: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
    Table 179    Rest of Latin America: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
    Table 180    Rest of Latin America: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)    
    Table 181    Rest of Latin America: Multiplex Assays Market, by End User, 2022–2031 (USD Million)    
    Table 182    Middle East & Africa: Multiplex Assays Market, by Type, 2022–2031 (USD Million)    
    Table 183    Middle East & Africa: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
    Table 184    Middle East & Africa: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
    Table 185    Middle East & Africa: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)    
    Table 186    Middle East & Africa: Multiplex Assays Market, by Application, 2022–2031 (USD Million)    
    Table 187    Middle East & Africa: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)    
    Table 188    Middle East & Africa: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
    Table 189    Recent Developments, by Company, 2021–2024

    List of Figures
    Figure 1    Market Ecosystem    
    Figure 2    Key Stakeholders    
    Figure 3    Research Process    
    Figure 4    Secondary Sources Referenced for This Study    
    Figure 5    Primary Research Techniques    
    Figure 6    Key Executives Interviewed    
    Figure 7    Breakdown of Primary Interviews (Supply Side & Demand Side)    
    Figure 8    Market Sizing and Growth Forecast Approach    
    Figure 9    Global Multiplex Assays Market, By Type, 2024 Vs. 2031 (USD Million)    
    Figure 10    Global Multiplex Assays Market, By Product, 2024 Vs. 2031 (USD Million)    
    Figure 11    Global Multiplex Assays Market, By Technology, 2024 Vs. 2031 (USD Million)    
    Figure 12    Global Multiplex Assays Market, By Application, 2024 Vs. 2031 (USD Million)    
    Figure 13    Global Multiplex Assays Market, By End User, 2024 Vs. 2031 (USD Million)    
    Figure 14    Global Multiplex Assays Market, By Geography    
    Figure 15    Impact Analysis of Market Dynamics    
    Figure 16    Pharmaceutical R&D Expenditures in The U.S., Europe, And China, 2010 Vs. 2019 Vs. 2021 (USD Million)    
    Figure 17    Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
    Figure 18    EU Regulatory Pathway – IVDR 2017/746    
    Figure 19    Porter’s Five Forces Analysis    
    Figure 20    Global Multiplex Assays Market, By Type, 2024 Vs. 2031 (USD Million)    
    Figure 21    Global Multiplex Assays Market, By Product, 2024 Vs. 2031 (USD Million)    
    Figure 22    Global Multiplex Assays Market, By Technology, 2024 Vs. 2031 (USD Million)    
    Figure 23    Global Multiplex Assays Market, By Application, 2024 Vs. 2031 (USD Million)    
    Figure 24    U.S.: New Molecular Entity (NME) Approvals (2011-2023)    
    Figure 25    Estimated Number of New Cancer Cases (In Million)    
    Figure 26    Global Multiplex Assays Market, By End User, 2024 Vs. 2031 (USD Million)    
    Figure 27    Global Pharmaceutical R&D Spending, 2012–2026 (USD Billion)    
    Figure 28    Global Multiplex Assays Market, By Region, 2024 Vs. 2031 (USD Million)    
    Figure 29    North America: Number of People Aged 65 Years and Above, 2015–2022 (In Million)    
    Figure 30    North America: Multiplex Assays Market Snapshot    
    Figure 31    U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)    
    Figure 32    Europe: Pharmaceutical Industry R&D Expenditure, 2000–2021 (USD Million)    
    Figure 33    Europe: Multiplex Assays Market Snapshot    
    Figure 34    U.K: Estimated Number of Cancer Cases, 2022–2030 (In Million)    
    Figure 35    U.K.: Number of People Diagnosed with Sexually Transmitted Infections, 2018–2020 (In Thousand)        
    Figure 36    Pharmaceutical R&D Expenditure, by Country, 2020 (USD Million)    
    Figure 37    Asia-Pacific: Multiplex Assays Market Snapshot    
    Figure 38    Latin America: Multiplex Assays Market Snapshot    
    Figure 39    Key Growth Strategies Adopted by Leading Players, 2021–2024    
    Figure 40    Multiplex Assays Market: Competitive Benchmarking (Based on Products)    
    Figure 41    Multiplex Assays Market: Competitive Benchmarking (Based on Geography)    
    Figure 42    Competitive Dashboard: Multiplex Assays Market    
    Figure 43    Seegene, Inc.: Financial Overview (2023)    
    Figure 44    F. Hoffmann-La Roche Ltd: Financial Overview (2023)    
    Figure 45    Thermo Fisher Scientific, Inc.: Financial Overview (2023)    
    Figure 46    Illumina, Inc.: Financial Overview (2023)    
    Figure 47    Qiagen N.V.: Financial Overview (2023)    
    Figure 48    Becton, Dickinson and Company: Financial Overview (2023)    
    Figure 49    Bio-Rad Laboratories: Financial Overview (2023)    
    Figure 50    DiaSorin S.p.A.: Financial Overview (2023)    
    Figure 51    PerkinElmer, Inc.: Financial Overview (2023)    
    Figure 52    Agilent Technologies, Inc.: Financial Overview (2023)    
    Figure 53    Abbott Laboratories: Financial Overview (2023)    
    Figure 54    Siemens Healthineers Ag: Financial Overview (2023)    
    Figure 55    Merck KGaA.: Financial Overview (2023)    
    Figure 56    Quanterix Corporation: Financial Overview (2023)

    Enquire
    Check Discount
    Author Name:

    Pranjali Takale, Mahesh Khillari

    Related Tag: Multiplex Assays Market Multiplex Immunoassay Multiplex ELISA Luminex assay Bead Based Assay Bead Based Immunoassay Multianalyte assays Multiplex Flow Assays Multiplex Flow Cytometry
    In Vitro Diagnostics
    Healthcare

    The Multiplex Assays Market is projected to reach $6.80 billion by 2031, at a CAGR of 8.9% during the forecast period. 

    Multiplex assays are used for the simultaneous detection of multiple analytes. Multiplex immunoassays provide an array of information on the roles of proteins, nucleic acid, and other biomolecules in varied biological processes, thereby providing clinicians with insight into the assessment and identification of disease progression.

    The growth of this market is attributed to several factors: the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.

    The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine is expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges for market growth.

    Here are the top 10 companies operating in the Multiplex Assays Market 

    Seegene, Inc. (South Korea)

    Founded in 1997 and headquartered in Seoul, South Korea, Seegene, Inc. develops molecular diagnostic reagents. The company operates in two product categories: Products and Systems. The company offers multiplex assay products from both categories. It provides products such as anyplex, magicplex, and seeplex. It also develops Dual Priming Oligonucleotide (DPO), Multiple Detection Temperatures (MuDT), and Tagging Oligonucleotide Cleavage and Extension (TOCE) technologies that help to identify and differentiate multiple pathogens in single reactions using real-time PCR methods.

    Seegene, Inc. offers its products to end users, including physicians and clinics, technicians and clinical labs, and life science researchers. The company has a geographic presence in the U.S., Canada, South Korea, Brazil, Mexico, Italy, the Middle East, and Germany. The company has more than 100 distributors worldwide.

    F. Hoffmann-La Roche AG (Switzerland)

    Founded in 1896 and headquartered in Basel, Switzerland, Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable divisions: Pharmaceuticals and Diagnostics, of which the Diagnostics division operates in the multiplex assay market.

    The Diagnostics division is engaged in developing a wide range of diagnostic products and solutions such as in vitro diagnostics solutions, molecular diagnostics, clinical chemistry & immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision support solutions.

    Roche has a geographic presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. Furthermore, the company has 23 manufacturing sites and 29 research and development sites worldwide.

    Thermo Fisher Scientific, Inc. (U.S.)

    Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific, Inc. offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions and Specialty Diagnostics segment offers multiplex assay products, such as instruments, protein and RNA assay kits, and accessories.

    Some of the major brands of Thermo Fisher are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. The company has a direct presence through its regional offices and production sites in the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, the UAE, India, China, Japan, Australia, and the Republic of Korea.

    Illumina, Inc. (U.S.)

    Incorporated in 1998 and headquartered in California, U.S., Illumina, Inc. provides sequencing- and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments: Core Illumina and GRAIL. The Core Illumina segment offers a multiplex assay solution to simplify workflows and accelerate analysis.

     The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K.

    Illumina distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of its subsidiaries are Illumina GmbH (Germany), Illumina Australia Pty. Ltd. (Australia), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands) and Illumina K.K. Japan (Japan).

    Qiagen N.V. (Netherlands.)

    Founded in 1984 and headquartered in Venlo, Netherlands, Qiagen N.V. is one of the leading providers of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company operates in five product groups: Sample technologies, Diagnostic solutions, PCR / Nucleic acid amplification, Genomics / NGS, and Others. The company markets its products mainly to two customer groups: Molecular Diagnostics products and Life Sciences products.

    The company offers multiplex assay products from the PCR / Nucleic acid amplification category and Diagnostic Solutions. PCR / Nucleic acid amplification product category consists of Research PCR consumables, Human ID / Forensics assay consumables, PCR instruments, and OEM consumables.

    Some of the major subsidiaries of the company are Qiagen AB (Sweden), Qiagen AG (Sweden), Qiagen GmbH (Germany), QIAGEN LLC (U.S.), QIAGEN China (Shanghai) Co. Ltd. (China), QIAGEN Inc. (Canada), QIAGEN K.K. (Japan), and QIAGEN S.r.l. (Italy).


    Becton, Dickinson and Company (U.S.)

    Founded in 1897 and headquartered in New Jersey, U.S., Becton, Dickinson and Company is a medical technology firm engaged in developing, manufacturing, and selling various medical devices, supplies, laboratory equipment, and diagnostic products. The company offers its products to healthcare institutions, life science researchers, physicians, clinics, diagnostic laboratories, and the pharmaceutical industry.

    The BD Life Sciences segment comprises two organizational units: Integrated Diagnostic Solutions and Biosciences. The company operates in the multiplex assay market through both segments.

    The company has manufacturing facilities outside the U.S. in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, and the U.K. Its subsidiaries include Becton Dickinson Canada Inc., Becton Dickinson GmbH (Germany), BD Rapid Diagnostic (Suzhou) Co., Ltd. (China), Becton Dickinson Asia Limited (Hong Kong), Becton, Dickinson B.V. (Netherlands), and Becton Dickinson India Private Limited (India).

    Bio-Rad Laboratories, Inc. (U.S.)

    Founded in 1952 and headquartered in California, U.S., Bio-Rad Laboratories, Inc. is a distributor and manufacturer of clinical diagnostics products and life science research. The company supplies and produces various systems and products for healthcare, analytical chemistry, and life sciences research. Bio-Rad Laboratories operates through two reportable segments: Clinical Diagnostics and Life Sciences, both segments provide products for multiplex assay.

    The company has a direct distribution source in over 35 countries outside the U.S., including Afghanistan, France, Hong Kong, Japan, Korea, Iceland, Germany, Australia, Spain, the Netherlands, and South Africa. Some of the major subsidiaries of the company include Bio-Rad Laboratories Pty. Limited (Australia), Bio-Rad Pacific Limited (U.S.), Bio-Rad Laboratories SAS (France), Bio-Rad Laboratories G.m.b.H. (Germany), Bio-Rad Laboratories K.K. (Japan), Bio-Rad Korea Limited (Korea), and Bio-Rad China Ltd. (Hong Kong).

    DiaSorin S.p.A (Italy)

    Founded in 1968 and headquartered in Saluggia, Italy, DiaSorin S.p.A. is a medical device company manufacturing immunodiagnostics and molecular diagnostics instruments, reagents, assays, and software. The company’s products cater to healthcare professionals’ diagnostic needs for diagnostic and treatment services for gastrointestinal infections, bone and mineral, endocrinology, hypertension, cancer, onco-hematology, and autoimmunity. DiaSorin’s diagnostic products are based on immunodiagnostics and molecular diagnostics technologies.

    DiaSorin has a direct presence in 24 countries and an indirect presence in 93 countries through its distributors. The company has ten manufacturing facilities in Italy, the U.K., Germany, the U.S., and Canada and nine R&D centers. Some of its subsidiaries are Luminex Molecular Diagnostics Inc. (Canada), Luminex Japan Corporation Ltd. (Japan), Luminex BV (Netherlands), Luminex Trading (Shanghai) Co. Ltd. (China), and others.

    PerkinElmer, Inc. (U.S.)

    Founded in 1937 and headquartered in Massachusetts, U.S., PerkinElmer, Inc. is a multinational company that offers products, solutions, and services for the life sciences, diagnostics, and applied markets. It operates through two reportable business segments: Discovery & Analytical Solutions and Diagnostics. The company offers multiplex assay through both operating business segments.

    The company’s manufacturing and R&D facilities are in several countries, including the U.S., China, Japan, and Germany. Furthermore, the company has a strong network of sales and marketing channels and service personnel in over 38 countries and sells its products and services in over 190 countries.

    PerkinElmer sells products and services predominantly through its distributors. Some of its subsidiaries are PerkinElmer Pty. Ltd. (Australia), PerkinElmer do Brasil Ltda. (Brazil), PerkinElmer Instruments (Shanghai) Co. Ltd. (China), PerkinElmer SAS (France), PerkinElmer Technologies GmbH & Co. KG (Germany), PerkinElmer Srl (Italy), PerkinElmer (India) Pvt Ltd. (India), and PerkinElmer Sverige AB (Sweden).

    Agilent Technologies, Inc. (U.S.)

    Founded in 1999 and headquartered in California, U.S., Agilent Technologies, Inc. provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three business segments: Life Sciences and Applied Markets, Agilent CrossLab, and Diagnostics and Genomics. The Diagnostics and Genomics segment offers the multiplex assay products market.

    Agilent has a presence across North America, Europe, Asia–Pacific, Latin America, and the Middle East & Africa and customers in over 110 countries through its subsidiaries and a strong distribution network. The company has research & development and manufacturing sites in California, Colorado, Delaware, Massachusetts, Texas, Vermont, Washington, Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K.

    Popular Mentions –  Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Merck KGaA (Germany), Quanterix Corporation (U.S.), and others.

     

      This website is secure and we do not share your personal information with any third party. privacy policy
      You will also receive a PDF copy of this sample in your mailbox.

      Proudly Partnering With Enterprises Around the Globe

      Accenture Amazon BCG-Corporate BioRad Boehringer-Ingelheim Deloitte Fujifilm Intel PEPSICO Samsung Olympus McKinsey LG-Chem Rosetta-Stone tata-consultancy-services SK Kao IQVIA Vemag Canada Genscript Grupo-Vilaseca HEC Highland-Metals-Inc
      Related Tag: Multiplex Assays Market Multiplex Immunoassay Multiplex ELISA Luminex assay Bead Based Assay Bead Based Immunoassay Multianalyte assays Multiplex Flow Assays Multiplex Flow Cytometry
      Request Sample
      Customize My Report
      Quick Contact
      Chat on Whatsapp
      Linkdin
      Whatsapp
      Feed
      Related Reports
      IVD Assay Development Market - Global Opportunity Analysis and Industry Forecast (2024-2031)

         Published Date: Oct-2024

      Protein Assays Market - Global Opportunity Analysis and Industry Forecast (2025-2032)

         Published Date: Aug-2024

      Lateral Flow Assays Market - Global Opportunity Analysis And Industry Forecast (2020-2027)

         Published Date: Jun-2021

      High Throughput Screening Market - Global Opportunity Analysis and Industry Forecast (2024-2031)

         Published Date: Mar-2024

      In-Vitro Toxicology/Toxicity Testing Market - Global Opportunity Analysis and Industry Forecast (2019-2025)

         Published Date: Nov-2019

      Table Of Content
      Download Free Sample Report
      Meticulous Research
      US
      +1 646-781-8004
      Meticulous Research
      Europe
      +44-203-868-8738
      Meticulous Research
      APAC
      +91-744-778-0008